Key result
In an in vitro setup, the CytoSorb whole blood adsorber reduced mean apixaban concentration from 414.3 ng/mL to 33 ng/mL after 30 minutes of adsorption.
Why the study?
The use of unopposed oral anticoagulants during cardiothoracic surgery causes severe bleeding and increased morbidity, prompting investigation into whether CytoSorb can reduce apixaban concentration and restore coagulation.
Does the CytoSorb whole blood adsorber reduce apixaban concentration in an in vitro model of reconstituted whole blood?
Does the CytoSorb whole blood adsorber reduce apixaban concentration in an in vitro model of reconstituted whole blood?
Absolute Event Rate: 33% vs 414.3%
In an in vitro model, the CytoSorb whole blood adsorber effectively reduced apixaban concentrations and normalized coagulation assays, suggesting potential utility for managing bleeding risk during cardiothoracic surgery.
Hypothesis-generating for CytoSorb in apixaban reversal; clinical studies required before any practice consideration.
No takes yet. Share an insight, caveat, or question.
Røed‐Undlien et al. (2022) studied Apixaban removal in cardiothoracic surgery context. CytoSorb whole blood adsorber vs. Baseline values (before spiking or at 0 minutes) was evaluated on Apixaban concentration. In an in vitro setup, the CytoSorb whole blood adsorber reduced mean apixaban concentration from 414.3 ng/mL to 33 ng/mL after 30 minutes of adsorption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: